XML 38 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]
1.
  Principles of Consolidation
 
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned), Milestone Education (wholly owned) and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]
2.
Basis of Presentation
 
The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form
10Q
and Article
8
of Regulation S-
X.
Accordingly, they do
not
include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present such interim results. Interim results are
not
necessarily indicative of the results of operations which
may
be expected for a full year or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto for the year ended
December 31, 2018,
included in Milestone Scientific's Annual Report on Form
10
-K.
Reclassification, Policy [Policy Text Block]
3.
  Reclassifications
 
Certain reclassifications have been made to the
2018
 financial statements to conform to the condensed  consolidated
2019
 financial statement presentation. These reclassifications had
no
effect on net loss or cash flows as previously reported.
Use of Estimates, Policy [Policy Text Block]
4.
  Use of Estimates
 
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, valuation of derivative liabilities, and valuation allowances on deferred tax assets. Actual results could differ from those estimates
.
Revenue from Contract with Customer [Policy Text Block]
5.
  Revenue Recognition
 
Under ASC
606,
the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition for arrangements within the scope of ASC
606,
the Company performs the following
five
steps: 
 
i.
 
identification of the promised goods or services in the contract;
ii.
 
determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;
iii.
 
measurement of the transaction price, including the constraint on variable consideration;
iv.
 
allocation of the transaction price to the performance obligations based on estimated selling prices; and
v.
 
recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC
606.
 
The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and
third
parties.
  
Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery. The Company has
no
obligation on product sales for any installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period. 
 
Sales Returns
 
The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights and the Company’s historical experience with returns and the amount of product in the distribution channel
not
consumed by patients and subject to return. The Company relies on historical return rates to estimate returns. In the future, if any of these factors and/or the history of product returns change, adjustments to the allowance for product returns
may
be required.
 
Financing and Payment
 
Our payment terms differ by geography and customer, but payment is generally required within
90
days from the date of shipment or delivery.
 
Disaggregation of Revenue
 
See Note
10
 for disaggregated revenue information
Consolidation, Variable Interest Entity, Policy [Policy Text Block]
6.
  Variable Interest Entities
 
A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. 
 
If the Company determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity.        
 
Because Milestone Scientific has a variable interest in Milestone China, it considered the guidance in ASC
810,
“Consolidation” as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary. Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:
 
 
Power Criterion: The power to direct the activities that most significantly impact the entity’s economic performance; and
 
Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE
 
Milestone Scientific does
not
have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has
not
been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the CEO and a group of significant shareholders, including the Milestone China CEO,  which have the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is
not
the primary beneficiary under ASC
810.
Accordingly, Milestone China has
not
been consolidated into the financial statements of Milestone Scientific and is accounted for under the equity method. See Note
6.
Cash and Cash Equivalents, Policy [Policy Text Block]
7.
Cash and Cash Equivalents
 
Milestone Scientific considers all highly liquid investments purchased with an original maturity of
three
months or less to be cash equivalents.
Accounts Receivable [Policy Text Block]
8.
Accounts Receivable
 
Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within
90
days from invoicing. As of
September 30, 2019
and
December 31, 2018, 
accounts receivable (non- related party) was recorded, net of allowance for doubtful accounts of
$10,000.
 
Inventory, Policy [Policy Text Block]
9
.  Inventories
 
Inventories principally consist of finished goods and component parts stated at the lower of cost (
first
-in,
first
-out method) or net realizable value. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence and product expiration requirements. As of
September 30, 2019
and
December 31, 2018,
inventory was recorded net of a valuation allowance for slow moving and defective inventory of approximately $
752
,000
and
$763,000,
  respectively. 
Equity Method Investments [Policy Text Block]
10.
  Equity Method Investments
 
Investments in which Milestone Scientific can exercise significant influence, but do
not
control, are accounted for under the equity method of accounting and are included in the long-term assets on the condensed consolidated balance sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the income tax line on the Condensed  Consolidated Statements of Operations.
Property, Plant and Equipment, Policy [Policy Text Block]
11.
  Furniture, Fixture and Equipment  
 
Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from
two
to
seven
years. The costs of maintenance and repairs are charged to operations as incurred. 
Intangible Assets, Finite-Lived, Policy [Policy Text Block]
12.
  Intangible Assets – Patents and Developed Technology
 
Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight--line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are amortized over the remaining estimated useful life of the patent. 
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
13.
  Impairment of Long-Lived Assets
 
Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may
not
be recoverable. The Company’s impairment review process is based upon an estimate of future undiscounted cash flow. Factors the Company considers that could trigger an impairment review include the following:
 
 
significant under performance relative to expected historical or projected future operating results;
 
significant changes in the manner of our use of the acquired assets or the strategy for our overall business;
 
significant negative industry or economic trends; and
 
significant technological changes, which would render the technology obsolete.
 
Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.
Research and Development Expense, Policy [Policy Text Block]
14.
  Research and Development
 
Research and development costs, which consist principally of new product development costs payable to
third
parties, are expensed as incurred. Advance payments for the research are amortized to expense either as services are performed or over the relevant service period using the straight-line method.
Income Tax, Policy [Policy Text Block]
15.
  Income Taxes
 
Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized
 
At
September 30, 2019
and
December 31, 2018,
we had
no
uncertain tax positions that required recognition in the condensed consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the condensed consolidated statements of operations.
No
interest and penalties are present for periods open. Tax returns for the 
2015,
2016,
2017,
and
2018
 years are subject to audit by federal and state jurisdictions. 
Earnings Per Share, Policy [Policy Text Block]
16.
  Basic and diluted net loss per common share
 
Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we applied the 
two
-class method to calculate basic and diluted net income (loss) per share of common stock, as our Series A Convertible Preferred Stock (which automatically converted in full into Common Stock on
May 2019 –
see Note
8
) was a participating security. The 
two
-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the 
two
-class method of computing earnings per share would
not
apply as our Series A Convertible Preferred Stock did
not
 contractually participate in our losses. 
 
The Company did
not
include any portion of outstanding options,  warrants or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented.  Such outstanding options and warrants totaled 
5,004,415
and
6,703,553
at
September 30, 2019
and
December 31, 2018,  
respectively. The application of the
two
-class method of computing earnings per share under general accounting principles for participating securities is
not
applicable during these periods because those securities do
not
contractually participate in its losses. 
Fair Value of Financial Instruments, Policy [Policy Text Block]
17.
  Fair Value of Financial Instruments
 
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in
one
of the following categories:
 
 
Level
1
inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.
 
Level
2
inputs which are defined as inputs other than quoted prices included within Level
1
that are observable for the assets or liabilities, either directly or indirectly.
 
Level
3
inputs are defined as unobservable inputs for the assets or liabilities.
 
Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and
may
affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
 
The following table provides the carrying value and fair value of the Company’s financial assets or liabilities (see Note
8
) measured at fair value on a recurring basis as of
September 30, 2019.
   
Carrying Value
   
Level 1
   
Level 2
   
Level 3
 
                                 
Derivative Warrants
  $
1,016,639
     
-
     
-
    $
1,016,639
 
Shares to be issued-liability
   
2,199,488
     
2,199,488
     
-
     
-
 
Total September 30, 2019
  $
3,216,127
    $
2,199,488
    $
-
    $
1,016,639
 
 
The following additional disclosures relate to the changes in fair value of the Company’s Level
3
instruments during the
nine
 months ended
September 30, 2019 :
   
September 30, 2019
 
Balance at beginning of year
  $
-
 
Warrants issued in connection with public offering (See Note 8)
   
376,497
 
Change in fair value of derivative liability
   
674,792
 
Exercise of liability classified warrants    
(34,650
)
Balance at end of period
  $
1,016,639
 
 
The Company had
no
assets or liabilities that were measured in the fair value on a recurring basis as of
December 31, 2018.
Derivatives, Policy [Policy Text Block]
18.
Derivative Liability
 
The Company does
not
use derivative instruments to hedge exposures to cash flow, market or foreign currency risks; however, the Company has certain financial instruments that qualify as derivatives and are classified as liabilities on the balance sheet. The Company evaluates all its financial instruments to determine if those instruments or any potential embedded components of those instruments qualify as derivatives that need to be separately accounted for in accordance with FASB ASC
815,
“Derivatives and Hedging”.  Derivatives satisfying certain criteria are recorded at fair value at issuance and marked-to-market at each balance sheet date with the change in the fair value recorded as income or expense. In addition, upon the occurrence of an event that requires the derivative liability to be reclassified to equity, the derivative liability is revalued to fair value at that date. See Note
8.
Share-based Payment Arrangement [Policy Text Block]
19.
  Stock-Based Compensation
 
Share-based payments to employees, including grants of employee stock options, is recognized in the condensed consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values. 
New Accounting Pronouncements, Policy [Policy Text Block]
20.
  Recent Accounting Pronouncements
 
On
January 1, 2019,
we adopted Accounting Standards Update
No.
2016
-
02,
Leases (Topic
842
) (ASU
2016
-
02
), by ASU
2018
-
11,
which supersedes the lease accounting guidance under Topic
840,
and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and
not
restating comparative periods. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.
 
In adopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transition guidance, which does
not
require the reassessment of the following: i) whether existing or expired arrangements are or contain a lease, ii) the lease classification of existing or expired leases, and iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. As of the adoption date, the Company identified
three
operating lease arrangements in which it is a lessee. The adoption of this standard resulted in the recognition of operating lease liabilities and right-of-use assets of
$166,292
in the Company’s condensed consolidated balance sheets. The adoption of the standard did
not
have a material effect on the Company’s statements of operations or statements of cash flows. For information regarding the impact of Topic
842
adoption, see Note
13
– Commitments.
 
On
November 28, 2018,
the Financial Accounting Standards Board (“FASB”) issued ASU
2018
-
13,
 Fair Value Measurement: Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (Topic
820
), which changes the fair value measurement disclosure requirements of ASC
820.
This ASU removes certain disclosure requirements regarding the amounts and reasons for transfers between Level
1
and Level
2
of the fair value hierarchy and the policy for timing of transfers between the levels. This ASU also adds disclosure requirements regarding unrealized gains and losses included in Other Comprehensive Income for recurring Level
3
fair value measurements and the range and weighted average of unobservable inputs used in Level
3
fair value measurements. ASU
2018
-
13
 is effective for all entities with fiscal years beginning after
December 15, 2019,
including interim periods therein. Early adoption is permitted for any eliminated or modified disclosures upon issuance of ASU
2018
-
13.
The Company is currently evaluating the impact of adopting this standard.
 
In
June 2016,
the FASB issued a new standard ASU
2016
-
13,
“Financial Instruments – Credit Losses” (Topic
326
). The new standard is intended to replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. It will be effective for all entities for fiscal years and interim periods, beginning after 
January 15, 2020.
We are currently evaluating the impact of adopting this guidance on our consolidated balance sheet, results of operation and financial condition.